PILA Stock Overview
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pila Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.30 |
| 52 Week High | kr4.17 |
| 52 Week Low | kr0.99 |
| Beta | 0.72 |
| 1 Month Change | 100.00% |
| 3 Month Change | 43.75% |
| 1 Year Change | -7.63% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| PILA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -3.0% | -3.0% | 0.9% |
| 1Y | -7.6% | 60.0% | 10.3% |
Return vs Industry: PILA underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: PILA underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| PILA volatility | |
|---|---|
| PILA Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: PILA's share price has been volatile over the past 3 months.
Volatility Over Time: PILA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1 | Dorte Gram | pilapharma.com |
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.
Pila Pharma AB (publ) Fundamentals Summary
| PILA fundamental statistics | |
|---|---|
| Market cap | kr54.72m |
| Earnings (TTM) | -kr9.93m |
| Revenue (TTM) | kr1.46m |
37.4x
P/S Ratio-5.5x
P/E RatioIs PILA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PILA income statement (TTM) | |
|---|---|
| Revenue | kr1.46m |
| Cost of Revenue | kr0 |
| Gross Profit | kr1.46m |
| Other Expenses | kr11.39m |
| Earnings | -kr9.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -678.73% |
| Debt/Equity Ratio | 0% |
How did PILA perform over the long term?
See historical performance and comparison